LONDON/NEW YORK (Reuters) - The co-leaders of research at Pfizer Inc split up on Wednesday as Martin Mackay left to head research at rival drugmaker AstraZeneca Plc , leaving Mikael Dolsten in charge.
Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results